日本語
.jpg)
2020
Shanghai 27 July 2020— Shanghai Haihe Biopharma Co., Ltd (referred as "Haihe Biopharma" or the “Company”), a leading biotech company focusing on the discovery and development of innovative oncology drugs, announced today that it has closed ￥1.20 Billion Series B Financing. This round of financing was led by Warburg Pincus and joined by CMBI, Legend Capital, CICC Capital, Chaos Investment, ALAN Asset Management, Ruihua Investment, and SSC. Series A investors BioTrack Capital, Yingke PE, Atlas Capital, CSPC and their affiliated parties continued to participate with follow-ons. The Company intends to use the proceeds from this round of financing to advance its pipeline, which includes the ongoing R&D and commercialization of multiple innovative oncology drugs globally. CEC Capital served as the exclusive financial adviser to Haihe Biopharma for this round of financing, and Boquan Capital served as the advisor for corporate restructuring.
"We are very pleased to embark on this new partnership with Haihe Biopharma, which also marks our first investment in China's rapidly growing biotech sector. We have been impressed by the Company's ability to innovate, its deep bench of talents as well as its extensive pipeline. By leveraging our global resources in the healthcare sector, we are committed to supporting the Company to bring better cancer treatments to benefit more patients."
CEC Capital served as the exclusive financial adviser to Haihe Biopharma for this round of financing. Gang Li, CEC Capital's Partner, commented, " Haihe Biopharma has been a star biotech company to watch since its inception due to the strong management team and robust product pipeline. This round of financing was led by globally reputable institutional investors, underscoring the leading position of Haihe Biopharma in the field of innovative oncology drug R&D. CEC will continue to provide comprehensive support for the Company in its efforts to become a world-class leading biopharma company.”
Haihe Biopharma is an innovation-driven biotechnology company in China focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs. Haihe brings life-saving therapies to cancer patients worldwide. It also has a research and management team with a global perspective, and is proactively mapping out the international development of innovative drugs. The Company currently has thirteen key drug candidates. As of today, Haihe Biopharma has received 21 IND or clinical trial approvals in four countries and regions.
Please visit the company website for more information: http://www.zztsbc.com
Warburg Pincus LLC is a leading global private equity firm focused on growth investing. The firm has more than $53 billion in private equity assets under management. The firm's active portfolio of more than 185 companies is highly diversified by stage, sector, and geography. Warburg Pincus is an experienced partner to management teams seeking to build durable companies with sustainable value. Founded in 1966, Warburg Pincus has raised 19 private equity funds, which have invested more than $84 billion in over 900 companies in more than 40 countries. The firm is headquartered in New York with 14 offices in 11 countries.
Warburg Pincus is one of the largest and most active private equity firms in China and Southeast Asia, having invested more than $14 billion in over 135 companies since 1994. As one of the most experienced institutional investors in China's healthcare industry, Warburg Pincus has invested over $1.7 billion in the areas of oncology, assisted reproduction, obstetrics & pediatrics, aesthetic services, as well as medical logistics & distribution. Our select current investments include Hygeia, Jinxin Fertility, Amcare, Evercare, and HTDK.
CMB International Capital Corporation Limited ("CMBI") is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group's synergy and coordination in domestic and overseas markets, as well as CMB's strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Equity and Structured Finance, etc.
Legend Capital, founded in April 2001，is the independent Venture Capital investment subsidiary under Legend Holdings. In February 2012, Legend Capital took the new Chinese name "君联(Junlian)". Legend Capital is now managing several USD funds and RMB funds with a total AUM over RMB50 bn, and focuses on innovation and growth enterprises with operations in China or related to China. By 2020, Legend Capital has invested in over 450 companies, of which over 70 are successfully listed on domestic or overseas capital market, besides, around 60 companies achieved exit through M&A.
CICC Capital Management Co., Ltd. ("CICC Capital" or "the Firm") is the flagship platform of China International Capital Corporation Limited ("CICC") for its global private equity businesses. The Firm is committed to becoming a globally leading private equity manager with an impactful brand, a large and stable investor base, superior investment capabilities, and prudent and efficient mid-and-back offices.
The Firm's product portfolio has been expanding steadily along three dimensions – investment strategy, industry focus, and geographical area. Currently, the Firm runs government-backed funds investing in emerging industries, funds focusing on restructuring of traditional sectors, USD and RMB funds of funds, and USD and RMB private equity funds with various strategies including venture capital, growth, buyout and distressed investment. With a total AUM of over RMB330 billion and 300 high-caliber professionals in its staff body, CICC Capital has become a leading private equity brand in China.
Shanghai Chaos Investment Group Co., Ltd. was registered in Pudong New Area in June 2005 with a registered capital of 298 million yuan. As a professional investment institution, its business involves commodity trade, commodity futures, stocks, and private equity investment management. In the investment practice, the company always adheres to the principle of "standardized management, professional research, steadfastness, and strict risk control". Since its establishment, it has continuously achieved excellent performance. The company has an experienced professional team, vigorous and enterprising. Through years of investment practice, this team has accumulated mature investment ideas and perfect risk control measures, and is good at capturing rapidly changing investment opportunities and calmly facing the great turbulence in the financial market. The broad research perspective enables the company to disperse risks through multi-disciplinary portfolios, and accurately grasp the market operation direction at the macro level, so as to ensure long-term stable development.
Beijing ALAN Asset Management Co., Ltd, was established in 2016 with a registered capital of 1.713 billion yuan (paid-in). Our shareholders include LANCY Co., Ltd. (002612.SZ), KEB Hana Bank, Hana Financial Group and other competitive investment institutions. ALAN AMC mainly focuses on equity & industrial investment, mezzanine & credit investment, real estate investment and other alternative assets investment opportunities. We are skilled in using a variety of investment methods and paying more attention in selecting industries and customers to achieve stable and profitable investment returns. Our headquartered is in Beijing, and we has established branch offices in Shanghai and Hong Kong.In the future,we plan to set up more branches in Asia to achieve an overall layout in the alternative investment area.
Jiangsu Ruihua Investment Holding Group Co., LTD., founded in July 2003, is mainly engaged in securities investment and asset management. It is one of the few private equity fund managers with an asset management scale of over 10 billion in China. The group's business covers the stock market, direct equity investment, merger and acquisition, private placement of listed companies, and financial futures and derivatives investment, thus achieving complete coverage of the industrial chain of China's capital market. The company focuses on the fields of big health, big consumption and TMT, and has created a new investment model of "hedging arbitrage based on value trend investment". At present, it has invested in more than hundreds of listed and unlisted companies, including primary market, private placement market and secondary market, and directly invested in 7 funds and 2 fund management companies in the primary market. A large number of companies are listed on the main board, second board and STAR Market. It is one of the most active institutions in the market. It has participated in more than 100 private placements and is known as "the king of private placement".
Shanghai Sci-Tech Innovation Center Equity Investment Fund (or Shanghai Sci-Tech Capital, SSC) is a Fund-Of-Fund founded in 2017 under the planning of the CPC Shanghai Municipal Committee and Shanghai Municipal Government. The initiation of Shanghai Sci-Tech Capital is led by Shanghai International Group (SIG), together with other cornerstone investors including Guosheng Group, Shanghai Trust, SIPG, Guotai Junan & Zhangjiang Hi-Tech Park. The manager of SSC is Shanghai Sci-Tech Innovation Center Capital Co., Ltd. SSC’s target AUM is RMB 30 billion, with a first round closing of RMB 6.52 billion in total. The fund focuses on investment of emerging strategic industries including TMT, healthcare, advanced manufacturing, clean technology and renewable energy. The fund invests in stages including angel, early stage, growth stage and late stage, with a primary focus on early and growth stage. The major region invested is Shanghai’s core area of sci-tech innovation center, with an extension to the surrounding Yangtze River Delta region and even entire China. More than 80% of the AUM are fund investment, and less than 20% are direct investment.
CEC Capital is a leading investment bank focused on new areas of growth for the TMT, consumer and health industries in China and abroad. CEC Capital has branches in Beijing, Shanghai, Los Angeles, and San Francisco. On the asset management side, CEC Capital is currently managing an RMB fund and a US dollar fund. CEC Capital also has FINRA/SIPC (formerly NASD) licensed employees. CEC Capital focuses on and has advantages within the medical and health industries. CEC Capital's healthcare team consists of professionals with experience working in R&D, funds, medical institutions, and large conglomerates. The team is defined by its keen investment logic and penetrating industry insights.
Boquan Equity Investment Management Co., Ltd. (“Boquan Capital”) is a new domestic fund that thoroughly implements the concept of "investment bank + investment". In terms of investment, the fund of Boquan Capital focuses on the medical and big health sector. Leveraging on its shareholder resources and team expertise, it selects investment targets with leading potential, and continuously boosts its presence and clout in the medical and big health sector. In the aspect of investment bank, the founder and team of Boquan Capital provide full life cycle capital market services for invested enterprises with their extensive investment banking resources, and empower the invested enterprises with first-rate capital market services, ensure significant improvements in both "quality" and "efficiency" of enterprises in the process of going public, strive to help enterprises constantly enhance their overall competitiveness after listing. In this way, the fund has created a unique and sustainable empowered investment model while achieving optimal returns.
